NIH collaborating with Clear Creek to develop COVID-19 therapies
First funding in new $3B pandemic therapies R&D initiative
NIH has signed the first funding and research collaboration agreement in Antiviral Program for Pandemics, a $3 billion initiative that that is intended to discover and develop next-generation COVID-19 therapeutics, as well as new candidate treatments for a range of RNA viruses that have pandemic potential.
The cooperative research and development agreement (CRADA) with Clear Creek Bio Inc. seeks to identify and develop a SARS-CoV-2 papain-like protease (PLpro) inhibitor that could treat COVID-19. PLpro is an essential coronavirus enzyme involved in viral replication and regulates host innate immune responses to viral infection...